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Background
A general cause for therapeutic failure in people is due to
the high resistance of HIV protease to antiretroviral drugs.
The aim of the present work is focused on two objectives:
to study the mutations responsible for the drug resistance
using Stanford database and how the existing ART drugs
are resistant to subtype d (wild type, major and minor
mutations) using docking studies.
Methods
The mutation frequency of subtype d in untreated persons
was obtained from Stanford DR database, http://hivdb.
stanford.edu/. Based on the database the wild type PTD
sequence was generated. Crystal structure 3LZS showed
more similarity based on BLASTp program. The protein
structure 3LZS was used as a template to build wild type,
major (L10V, N37D, K69Y), minor (K20I, L33I, P39T,
Q61N), major+minor mutants of PTD using Modeller9v7.
The docking studies of protease inhibitors (atazanavir, dar-
unavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir,
tipranavir) with the wild type and mutant models were
carried using AutoDock 4.2.5.
Results
The docking studies revealed that contribution of high tor-
sional energy in atazanavir affects the binding energy and
leads to high level resistance to the wild type and the
mutants. Indinavir showed susceptibility for the wild type
PTD whereas nelfinavir showed susceptibility to all
mutants and the susceptibility was due to less number of
torsions and increased van der Waals, hydrogen bonding,
desolvation and electrostatic energy contributions.
Conclusion
The developed wild type and mutant model of PTD pro-
vides an insight to understand the effect of mutations
and resistance towards the protease inhibitors.
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